Business
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, May 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 14 update. The update is from an ongoing 30-day case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who experienced COVID Rebound following intervention with Pfizer’s Paxlovid. ABSTRACT: COVID-19 and Acute Sequelae of SARS-CoV-2 (PASC), or Long COVID, are major public health problems. Emerging evidence suggests the PASC, for many, may in fact be due to persistent SARS-CoV-2 infection that is able to evade vaccine or infection-induced immunity and cause recurring and persistent symptoms. PASC does not appear to protect against new acute SARS-CoV-2 infection, and PASC may in fact contribute to poor outcomes in new acute infections and/or recurrent symptoms from prior infection. We report a case of a patient with a history of multiple SARS-CoV-2 infections and persistent PASC, who received the therapeutic intervention Paxlovid following a positive PCR test and experienced severe rebound of symptoms starting on Day 5, the final day of Paxlovid treatment. The patient’s symptoms were resolved following an initial 14-day cleanse with 3CL protease inhibitor immune support dietary supplement Tollovid®. SUMMARIZED CASE REPORT A 53-year-old female in excellent physical condition experienced four COVID-19 infections over the course of two years between March 13, 2020 through April 20, 2022.  The patient is a single mother with a son in college and lived a very reclusive lifestyle.  Her current blood panels suggest that she is now immunocompromised.  Before the first COVID-19 infection on March 13, 2020 the patient did 3 to 6 miles of daily trail running four times per week.  She also taught school three times per week and cycled the 8-mile distance to work each time.  She was 5 ft 6 in, 160 lb, had a resting pulse rate of 60, and had all blood work within normal limits.  At the time immediately prior to beginning intervention with Tollovid in this case study she weighed 185 lb, her blood work was abnormal, and she was expe...